Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act; H.R. 6485/S. 43, Skinny Labels, Big Savings Act; Biosimilar industry issues
H.R.3269/S.2276, Eliminating Thickets to Increase Competition (ETHIC) Act H.R.6485/S.43, Skinny Labels, Big Savings Act Issues related to pharmaceutical manufacturing Issues related to pharmaceutical patents
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FRESENIUS KABI USA LLC via WILEY REIN LLP
2026 · third_quarter · Q3
H.R.3269/S.2276, Eliminating Thickets to Increase Competition (ETHIC) Act H.R.6485/S.43, Skinny Labels, Big Savings Act Issues related to pharmaceutical manufacturing Issues related to pharmaceutical patents
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA LLC via WILEY REIN LLP
2026 · third_quarter · RR
Source: Senate LDA
H.R.3269/S.2276, Eliminating Thickets to Increase Competition (ETHIC) Act H.R.6485/S.43, Skinny Labels, Big Savings Act Issues related to pharmaceutical manufacturing Issues related to pharmaceutical patents
H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act; H.R. 6485/S. 43, Skinny Labels, Big Savings Act; Biosimilar industry issues
H.R.3269/S.2276, Eliminating Thickets to Increase Competition (ETHIC) Act H.R.6485/S.43, Skinny Labels, Big Savings Act Issues related to pharmaceutical manufacturing Issues related to pharmaceutical patents
H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act; H.R. 6485/S. 43, Skinny Labels, Big Savings Act; Biosimilar industry issues
H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act; H.R. 6485/S. 43, Skinny Labels, Big Savings Act; Biosimilar industry issues
H.R.3269/S.2276, Eliminating Thickets to Increase Competition (ETHIC) Act H.R.6485/S.43, Skinny Labels, Big Savings Act Issues related to pharmaceutical manufacturing Issues related to pharmaceutical patents
H.R. 1506, Fair And Immediate Release of (FAIR) Generic Drugs Act S. 64, Preserve Access to Affordable Generics and Biosimilars Act; S. 659, Biologic Patent Transparency Act S. 659, Biologic Patent Transparency Act Issues related to the Biologics Price Competition and Innovation Act; Issues related to drug pricing / patent stacking; Issues related to Inter Partes and post-grant review; Issues related to Biosimilar User Fee Act; Issues related to biologic exclusivity; Issues related to patent settlements; Issues related to Food Drug and Cosmetic Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: WILEY REIN LLP
H.R. 1506, Fair And Immediate Release of (FAIR) Generic Drugs Act S. 64, Preserve Access to Affordable Generics and Biosimilars Act; S. 659, Biologic Patent Transparency Act S. 659, Biologic Patent Transparency Act Issues related to the Biologics Price Competition and Innovation Act; Issues related to drug pricing / patent stacking; Issues related to Inter Partes and post-grant review; Issues related to Biosimilar User Fee Act; Issues related to biologic exclusivity; Issues related to patent settlements; Issues related to Food Drug and Cosmetic Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: WILEY REIN LLP
S. 64, Preserve Access to Affordable Generics and Biosimilars Act; S. 659, Biologic Patent Transparency Act
Biologic Patent Transparency Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: WILEY REIN LLP
H.R. 1506, Fair And Immediate Release of (FAIR) Generic Drugs Act S. 64, Preserve Access to Affordable Generics and Biosimilars Act; S. 659, Biologic Patent Transparency Act S. 659, Biologic Patent Transparency Act Issues related to the Biologics Price Competition and Innovation Act; Issues related to drug pricing / patent stacking; Issues related to Inter Partes and post-grant review; Issues related to Biosimilar User Fee Act; Issues related to biologic exclusivity; Issues related to patent settlements; Issues related to Food Drug and Cosmetic Act
Biologic Patent Transparency Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: WILEY REIN LLP
S. 64, Preserve Access to Affordable Generics and Biosimilars Act; S. 659, Biologic Patent Transparency Act
H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act; H.R. 6485/S. 43, Skinny Labels, Big Savings Act; Biosimilar industry issues
ASSOCIATION FOR ACCESSIBLE MEDICINES via WILEY REIN LLP
2019 · first_quarter · 1T
H.R. 1506, Fair And Immediate Release of (FAIR) Generic Drugs Act S. 64, Preserve Access to Affordable Generics and Biosimilars Act; S. 659, Biologic Patent Transparency Act S. 659, Biologic Patent Transparency Act Issues related to the Biologics Price Competition and Innovation Act; Issues related to drug pricing / patent stacking; Issues related to Inter Partes and post-grant review; Issues related to Biosimilar User Fee Act; Issues related to biologic exclusivity; Issues related to patent settlements; Issues related to Food Drug and Cosmetic Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR ACCESSIBLE MEDICINES via WILEY REIN LLP
2019 · first_quarter · RR
S. 64, Preserve Access to Affordable Generics and Biosimilars Act; S. 659, Biologic Patent Transparency Act